Blincyto
Blinatumomab Increases Disease-Free Survival for Children With Leukemia
Children with B-acute lymphoblastic leukemia who received blinatumomab plus standard chemotherapy were 61% less ...
JANUARY 15, 2025
T-Cell Engager Called Major Breakthrough In Children With B-Cell ALL
The T-cell engager blinatumomab (Blincyto, Amgen) was characterized as a “major breakthrough” in ...
DECEMBER 20, 2024
Blincyto Approved as Consolidation for CD19-Positive Philadelphia Chromosome–Negative B-Cell Precursor ALL
The FDA has approved blinatumomab (Blincyto, Amgen) for adult and pediatric patients aged 1 month and older with ...
JUNE 17, 2024
Report from ASH 2019: Large Benefit With Blinatumomab in Trial of Younger B-ALL Patients
ORLANDO, FLA.—In children, adolescents and young adults with B-cell acute lymphoblastic leukemia who have ...
DECEMBER 23, 2019
FDA Approves Blincyto for ALL Pts with Minimal Residual Disease
Blincyto is the first and only FDA-approved therapy for patients who have ALL that is in remission but who still ...
MARCH 29, 2018
Blincyto Approved for Relapsed or Refractory B-cell ALL
The FDA granted full approval to blinatumumab for relapsed or refractory B-cell precursor acute lymphoblastic ...
JULY 12, 2017